Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Proof-of-concept Study With NVDX3, an Osteogenic Implant of Human Allogenic Origin, in the Treatment of Low Grade Degenerative Lumbar Spondylolisthesis by Interbody Spine Fusion in Adults.

NCT05961956 is registered in ClinicalTrials.gov with Novadip Biosciences as lead sponsor.

NCT NCT05961956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05961956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Proof-of-concept Study With NVDX3, an Osteogenic Implant of Human Allogenic Origin, in the Treatment of Low Grade Degenerative Lumbar Spondylolisthesis by Interbody Spine Fusion in Adults.
Lead sponsor
Novadip Biosciences
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 12, 2023
Completion date
April 18, 2026
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

degenerative lumbar spondylolisthesis